Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.72 |
| ▸ | NPC1 | O15118 | 7/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.72 |
| ▸ | TP53 | P04637 | 3/20 | 0.72 |
| ▸ | HTT | P42858 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | DHODH | Q02127 | 2/20 | 0.72 |
| ▸ | GMNN | O75496 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | HTR1A | P08908 | 1/20 | 0.72 |
| ▸ | THRB | P10828 | 1/20 | 0.72 |
| ▸ | PIM1 | P11309 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | MAOA | P21397 | 1/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.72 |
| ▸ | HTR2A | P28223 | 1/20 | 0.72 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.72 |
| ▸ | CCKBR | P32239 | 1/20 | 0.72 |
| ▸ | MC4R | P32245 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8812469 | 0.93 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2TP53HTT | |
| SCHEMBL8812360 | 0.89 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2TP53HTT | |
| SCHEMBL11441650 | 0.88 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2TP53HTT | |
| SCHEMBL20456411 | 0.88 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2TP53HTT | |
| SCHEMBL6415832 | 0.87 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2TP53HTT | |
| SCHEMBL8813278 | 0.85 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2TP53HTT | |
| SCHEMBL15711547 | 0.85 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2TP53HTT | |
| SCHEMBL9812368 | 0.85 | RAB9A (0.78) | RAB9ANPC1SMN1; SMN2TP53HTT | |
| SCHEMBL7558642 | 0.85 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2TP53HTT | |
| SCHEMBL8813186 | 0.84 | DHODH (0.71) | RAB9ANPC1SMN1; SMN2TP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127532-A1 | Method for synthesizing leflunomide | AVRUTOV ILYA (IL) | 2004-07-01 | — | — | US | claimed |
| US-6723855-B2 | CHLORINATING 5-METHYLISOXAZOLE-4-CARBOXYLIC ACID BY REACTING WITH CHLORINATING AGENT TO FORM 5-METHYLISOXAZOLE-4-CARBOXYLIC ACID CHLORIDE, REACTING WITH 4-TRIFLUOROMETHYLANILINE IN PRESENCE OF ALKALI METAL OR ALKALINE EARTH METAL BICARBONATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-04-20 | — | — | US | claimed |
| JP-2004500380-A | — | — | 2004-01-08 | — | — | JP | claimed |
| EP-1257270-A4 | A METHOD FOR SYNTHESIZING LEFLUNOMIDE | TEVA PHARMA (IL) | 2003-05-07 | — | — | EP | claimed |
| EP-1257270-A1 | A METHOD FOR SYNTHESIZING LEFLUNOMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-11-20 | — | — | EP | claimed |
| US-20020022646-A1 | Method for systhesizing leflunomide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-02-21 | — | — | US | claimed |
| WO-2001060363-A1 | A METHOD FOR SYNTHESIZING LEFLUNOMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2001-08-23 | — | — | WO | claimed |
| EP-3786164-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | Ting Therapeutics LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20180161340-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2018-06-14 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| EP-1257270-B1 | A METHOD FOR SYNTHESIZING LEFLUNOMIDE | TEVA PHARMA (IL) | 2005-04-13 | — | — | EP | disclosed |
| EP-1473035-A1 | Leflunomide of high purity | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-11-03 | — | — | EP | disclosed |
| EP-1473035-A1 | Leflunomide of high purity | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-11-03 | — | — | EP | disclosed |
| US-20040127532-A1 | Method for synthesizing leflunomide | AVRUTOV ILYA (IL) | 2004-07-01 | — | — | US | disclosed |
| EP-1257270-A4 | A METHOD FOR SYNTHESIZING LEFLUNOMIDE | TEVA PHARMA (IL) | 2003-05-07 | — | — | EP | disclosed |
| EP-1257270-A1 | A METHOD FOR SYNTHESIZING LEFLUNOMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-11-20 | — | — | EP | disclosed |
| US-20020022646-A1 | Method for systhesizing leflunomide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-02-21 | — | — | US | disclosed |
| WO-2001060363-A1 | A METHOD FOR SYNTHESIZING LEFLUNOMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | RAB9A 704/4885NPC1 480/4885SMN1; SMN2 709/4885 |
| US-20020022646-A1 | Method for systhesizing leflunomide | FAH, LEF1, HMGCR | RAB9A 2074/4885NPC1 1244/4885SMN1; SMN2 570/4885 |
| US-20180161340-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | CDK2, CDK5, CDK20 | RAB9A 4509/4885NPC1 1827/4885SMN1; SMN2 2538/4885 |
| US-20040127532-A1 | Method for synthesizing leflunomide | LEF1, CYP3A5, CYP2F1 | RAB9A 2319/4885NPC1 956/4885SMN1; SMN2 1333/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | RAB9A 1324/4885NPC1 1815/4885SMN1; SMN2 3947/4885 |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | RAB9A 704/4885NPC1 480/4885SMN1; SMN2 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.